What's Behind The Jump In Lunai Bioworks Stock?

Lunai Bioworks Inc. (NASDAQ: LNAI) announced a strategic acquisition of blood-brain barrier delivery technology and Alzheimer’s drug assets from the Clemann Group for $20 million, structured as Series B Convertible Preferred shares at a fixed conversion price of $1.50. Following this announcement, Lunai's stock surged by 57.29%, reaching approximately 63 cents per share. This acquisition enhances Lunai's capabilities in delivering therapeutics for central nervous system diseases, particularly Alzheimer's.